Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment

Chunlan Jing; Shenmao Chen; Sehajdev Singh Bhatia; Bowen Li; Hongze Liang; Chaozong Liu; Zhenjiang Liang; Junying Liu; Haiyan Li; Ziyu Liu; Hui Tan; Lingling Zhao

doi:10.1016/j.polymertesting.2022.107584

Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment

Chunlan Jing
, Shenmao Chen
, Sehajdev Singh Bhatia
, Bowen Li
, Hongze Liang
, Chaozong Liu^*
, Zhenjiang Liang
, Junying Liu
, Haiyan Li
, Ziyu Liu^*
, Hui Tan^*
, Lingling Zhao^*

^*Corresponding author for this work

Ningbo University
University College London
James Paget University Hospitals NHS Foundation Trust
Shenzhen Children's Hospital
Shenzhen University

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Bone-targeted polymeric nanoparticles for alendronate delivery based on Poly (lactic-co-glycolic acid) conjugated chitosan (CS-PLGA) and alendronate conjugated PLGA (Alen-PLGA) are fabricated and their superior performances are evaluated. The nanoparticles exhibited sustained Alen release without obvious burst release and good cytocompatibility against MC3T3 cells. Alen-modified nanoparticles demonstrated a high affinity to hydroxyapatite, which is the main mineral component of bone, indicating their feasibility for bone-targeted delivery. In addition, unlike nanoparticles without Alen, Alen-modified nanoparticles were preferentially taken up by MC3T3 cells, compared to HDF cells, revealing their specific uptake for osteoblast-like cells. Thus, the Alen-modified nanoparticles can potentially be developed as bone-targeted carriers for osteoporosis treatment.

Original language	English
Article number	107584
Journal	Polymer Testing
Volume	110
DOIs	https://doi.org/10.1016/j.polymertesting.2022.107584
State	Published - Jun 2022
Externally published	Yes

Keywords

Alendronate
Bone-targeted
Nanoparticles
Osteoporosis

Access to Document

10.1016/j.polymertesting.2022.107584

Cite this

@article{6ae2ac4685814092b7179ac4d5465da6,

title = "Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment",

abstract = "Bone-targeted polymeric nanoparticles for alendronate delivery based on Poly (lactic-co-glycolic acid) conjugated chitosan (CS-PLGA) and alendronate conjugated PLGA (Alen-PLGA) are fabricated and their superior performances are evaluated. The nanoparticles exhibited sustained Alen release without obvious burst release and good cytocompatibility against MC3T3 cells. Alen-modified nanoparticles demonstrated a high affinity to hydroxyapatite, which is the main mineral component of bone, indicating their feasibility for bone-targeted delivery. In addition, unlike nanoparticles without Alen, Alen-modified nanoparticles were preferentially taken up by MC3T3 cells, compared to HDF cells, revealing their specific uptake for osteoblast-like cells. Thus, the Alen-modified nanoparticles can potentially be developed as bone-targeted carriers for osteoporosis treatment.",

keywords = "Alendronate, Bone-targeted, Nanoparticles, Osteoporosis",

author = "Chunlan Jing and Shenmao Chen and Bhatia, \{Sehajdev Singh\} and Bowen Li and Hongze Liang and Chaozong Liu and Zhenjiang Liang and Junying Liu and Haiyan Li and Ziyu Liu and Hui Tan and Lingling Zhao",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jun,

doi = "10.1016/j.polymertesting.2022.107584",

language = "英语",

volume = "110",

journal = "Polymer Testing",

issn = "0142-9418",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment

AU - Jing, Chunlan

AU - Chen, Shenmao

AU - Bhatia, Sehajdev Singh

AU - Li, Bowen

AU - Liang, Hongze

AU - Liu, Chaozong

AU - Liang, Zhenjiang

AU - Liu, Junying

AU - Li, Haiyan

AU - Liu, Ziyu

AU - Tan, Hui

AU - Zhao, Lingling

PY - 2022/6

Y1 - 2022/6

N2 - Bone-targeted polymeric nanoparticles for alendronate delivery based on Poly (lactic-co-glycolic acid) conjugated chitosan (CS-PLGA) and alendronate conjugated PLGA (Alen-PLGA) are fabricated and their superior performances are evaluated. The nanoparticles exhibited sustained Alen release without obvious burst release and good cytocompatibility against MC3T3 cells. Alen-modified nanoparticles demonstrated a high affinity to hydroxyapatite, which is the main mineral component of bone, indicating their feasibility for bone-targeted delivery. In addition, unlike nanoparticles without Alen, Alen-modified nanoparticles were preferentially taken up by MC3T3 cells, compared to HDF cells, revealing their specific uptake for osteoblast-like cells. Thus, the Alen-modified nanoparticles can potentially be developed as bone-targeted carriers for osteoporosis treatment.

AB - Bone-targeted polymeric nanoparticles for alendronate delivery based on Poly (lactic-co-glycolic acid) conjugated chitosan (CS-PLGA) and alendronate conjugated PLGA (Alen-PLGA) are fabricated and their superior performances are evaluated. The nanoparticles exhibited sustained Alen release without obvious burst release and good cytocompatibility against MC3T3 cells. Alen-modified nanoparticles demonstrated a high affinity to hydroxyapatite, which is the main mineral component of bone, indicating their feasibility for bone-targeted delivery. In addition, unlike nanoparticles without Alen, Alen-modified nanoparticles were preferentially taken up by MC3T3 cells, compared to HDF cells, revealing their specific uptake for osteoblast-like cells. Thus, the Alen-modified nanoparticles can potentially be developed as bone-targeted carriers for osteoporosis treatment.

KW - Alendronate

KW - Bone-targeted

KW - Nanoparticles

KW - Osteoporosis

UR - https://www.scopus.com/pages/publications/85128349017

U2 - 10.1016/j.polymertesting.2022.107584

DO - 10.1016/j.polymertesting.2022.107584

M3 - 文章

AN - SCOPUS:85128349017

SN - 0142-9418

VL - 110

JO - Polymer Testing

JF - Polymer Testing

M1 - 107584

ER -

Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this